Scholarlink

<p>A paper-based electrochemical aptasensor (PEA) is reported for the simultaneous detection of extracellular dopamine (DA) and serotonin (SE) in human brain samples, enabling the assessment of neurotransmitter imbalances associated with Alzheimer’s disease (AD). The PEA integrates a dual-selectivity strategy that combines aptamer-mediated molecular recognition with potential-resolved electrochemical neurotransmitters discrimination, allowing reliable differentiation between healthy and AD-diagnosed left prefrontal cortex tissues based on altered dopaminergic and serotonergic levels. Thiolated aptamers immobilized onto gold nanoparticles (AuNPs) at the paper electrode interface provide selective neurotransmitter biorecognition, while the distinct oxidation potentials of DA (+ 0.10&#xa0;V) and SE (+ 0.25&#xa0;V <i>vs</i>. Ag/AgCl) enable their label-free, simultaneous quantification on a single disposable electrode. The PEA read biologically meaningful concentration shifts across a clinically relevant dynamic range, spanning levels characteristic of healthy tissue to those observed in advanced pathological stages. The PEA approach highlights its potential for liquid biopsy–oriented neurochemical monitoring and supports its application in multiplexed biosensing within organ-on-a-chip systems, enabling early diagnostic strategies for neurodegenerative diseases.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Label-free paper-based electrochemical aptasensor with tunable selectivity for assessing neurotransmitter imbalance in Alzheimer’s disease

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月7日

查看全文
  • Silvia Dortez,
  • Miriam Chávez,
  • Ana Montero-Calle,
  • Rodrigo Barderas,
  • Marta Pacheco,
  • Alberto Escarpa

摘要

A paper-based electrochemical aptasensor (PEA) is reported for the simultaneous detection of extracellular dopamine (DA) and serotonin (SE) in human brain samples, enabling the assessment of neurotransmitter imbalances associated with Alzheimer’s disease (AD). The PEA integrates a dual-selectivity strategy that combines aptamer-mediated molecular recognition with potential-resolved electrochemical neurotransmitters discrimination, allowing reliable differentiation between healthy and AD-diagnosed left prefrontal cortex tissues based on altered dopaminergic and serotonergic levels. Thiolated aptamers immobilized onto gold nanoparticles (AuNPs) at the paper electrode interface provide selective neurotransmitter biorecognition, while the distinct oxidation potentials of DA (+ 0.10 V) and SE (+ 0.25 V vs. Ag/AgCl) enable their label-free, simultaneous quantification on a single disposable electrode. The PEA read biologically meaningful concentration shifts across a clinically relevant dynamic range, spanning levels characteristic of healthy tissue to those observed in advanced pathological stages. The PEA approach highlights its potential for liquid biopsy–oriented neurochemical monitoring and supports its application in multiplexed biosensing within organ-on-a-chip systems, enabling early diagnostic strategies for neurodegenerative diseases.

Graphical Abstract